
Celularity Inc.: updates and filings
Price
$0.57
November 17, 2026Market cap $19M
What Ploutos Investor adds for Celularity
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 51% since Oct 20, 2026, when the 10-Q these figures come from was filed ($1.26 then, $0.62 on Nov 16, 2026). The figures date from before that move.10-Q
- A figure that did not match the numbers it is built from has been left out.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
A rough estimate from when it has reported before, which has varied. The company announces the date itself.
October 2026
September 2026
August 2026
July 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- Nov 10, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Nov 10, 2026Additional annual meeting materialFormDEFA14A
- Nov 10, 2026Annual meeting proxy statementFormDEF 14A
- Oct 29, 2026Other material eventsForm8-K
- Oct 29, 2026Preliminary proxy statementFormPRE 14A
- Oct 20, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Oct 20, 2026Annual report (amendment)for the period to Dec 31, 2025Form10-K/A
- Sep 29, 2026Officer or director changeForm8-K
- Sep 29, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Sep 28, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Sep 28, 2026Material agreement entered, new material financial obligation, unregistered sale of shares, officer or director changeForm8-K
- Sep 14, 2026Other material eventsForm8-K
- Aug 14, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- Aug 7, 2026Officer or director changeForm8-K
- Jul 29, 2026Delisting noticeForm8-K
- Jul 22, 2026One of its securities removed from an exchange (usually a matured note)Form25-NSE
- Jun 30, 2026Material agreement entered, new material financial obligation, officer or director changeForm8-K
- Jun 25, 2026Officer or director changeForm8-K
- Jun 23, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Jun 12, 2026Delisting noticeForm8-K
- Jun 3, 2026Officer or director change, Regulation FD disclosureForm8-K
- May 28, 2026Material agreement entered, new material financial obligationForm8-K
- May 15, 2026Notice that the quarterly report will be filed lateFormNT 10-Q
- Apr 30, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Nov 10, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Nov 10, 2026 | DEFA14A | Additional annual meeting material | Document |
| Nov 10, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Oct 29, 2026 | 8-K | Other material events | Document |
| Oct 29, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Oct 20, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Oct 20, 2026 | 10-K/A | Annual report (amendment)for the period to Dec 31, 2025 | Document |
| Sep 29, 2026 | 8-K | Officer or director change | Document |
| Sep 29, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Sep 28, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Sep 28, 2026 | 8-K | Material agreement entered, new material financial obligation, unregistered sale of shares, officer or director change | Document |
| Sep 14, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Aug 7, 2026 | 8-K | Officer or director change | Document |
| Jul 29, 2026 | 8-K | Delisting notice | Document |
| Jul 22, 2026 | 25-NSE | One of its securities removed from an exchange (usually a matured note) | Document |
| Jun 30, 2026 | 8-K | Material agreement entered, new material financial obligation, officer or director change | Document |
| Jun 25, 2026 | 8-K | Officer or director change | Document |
| Jun 23, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Jun 12, 2026 | 8-K | Delisting notice | Document |
| Jun 3, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| May 28, 2026 | 8-K | Material agreement entered, new material financial obligation | Document |
| May 15, 2026 | NT 10-Q | Notice that the quarterly report will be filed late | Document |
| Apr 30, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Nov 5, 2018.
The full analysis
What do Celularity's filings show?
The filings are where every one of Celularity's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.